seed
Stage
2024
Founded
1
Investors
About
Archon Biosciences develops computationally designed Antibody Cages (AbCs), a novel class of biologics that leverage generative AI and protein design to target previously inaccessible therapeutic pathways.
Explore Archon Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.